- CA$29.26m
- CA$121.11m
Brief: Resverlogix Plans Covid-19 Clinical Trial Program Launch
Brief: Resverlogix Seeking To Collaborate With Organizations Testing Therapies For Sars-Cov-2
Brief: Resverlogix Receives US FDA Breakthrough Therapy Designation For Apabetalone
Brief: Resverlogix Announces Change To Its Board Of Directors
Brief: Resverlogix Announces Topline Results In Betonmace Phase 3 Epigenetics Trial
Brief: Resverlogix Announces Us$12 Million Debenture Financing And Full Repayment Of Loan
Brief: Resverlogix Provides Update On Betonmace Phase 3 Trial
Brief: Eastern Capital Exercised Warrants To Acquire 5 Mln Shares Of Resverlogix At Cash Price Of C$0.75/Share, For Total Consideration Of C$3.75 Mln
Brief: Resverlogix Announces Publication On Apabetalone In Clinical Epigenetics
Brief: Resverlogix’s Betonmace Phase 3 Epigenetics Trial Completes Final Safety Visits
Brief: Resverlogix Announces Pricing Of Unit Offering
Brief: Resverlogix Announces 3-Month Loan Extension
Brief: Resverlogix's Betonmace Phase 3 Trial Reaches Its Targeted 250 Major Adverse Cardiac Events
Brief: Resverlogix Announces $15.1 Mln Of Private Placements
Brief: Resverlogix Gets Positive DSMB Recommendation For Phase 3 Study Of Apabetalone
Brief: Resverlogix Announces Eighth Positive DSMB Recommendation For Phase 3 Study Of Apabetalone
Brief: Resverlogix Announces $26 Million Private Placement
Brief: Resverlogix - Seventh Positive Recommendation From Data Safety Monitoring Board For Study Of Apabetalone
Brief: Resverlogix Says Intends To Pursue U.S. Listing